Journal of Ayurveda and integrative medicine · 2026
Therapeutic effects of Ghrita Manda Ashchyotana on tear film stability, corneal integrity, and IL-6 expression in a benzalkonium chloride-induced murine dry eye model.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Janardhanan Ramya Shruthi, Kundrinmani Sivabalaji, Nagaraj Ashwini Belludi
Аннотация
BACKGROUND: Dry Eye (DE) is a condition marked by tear film instability and chronic inflammation, leading to visual impairment. Conventional artificial tears often contain preservatives that exacerbate DE and fail to address underlying tissue damage. In Ayurveda, DE symptoms corelates with Sushkakshipaka, managed by normalizing vata pitta derangement. This study evaluates the mechanism of Ghrita MandaAshchyotana in a Benzalkonium Chloride (BAC)-induced murine dry eye model.
METHODOLOGY: 12 male Swiss albino mice (24 eyes) were divided into: saline-treated controls (3 mice), and dry eye-induced mice treated with either Ghrita Manda (Trial), preservative-free eye drops (Positive control), or left untreated (Negative control). Assessments included Tear Film Break-Up Time (TFBUT), fluorescein scores, corneal Hematoxylin and Eosin (H&E) staining, and IL-6 expression after 14 days.
RESULTS: Ghrita Manda significantly improved TFBUT and reduced fluorescein scores compared to the negative control (p < 0.001). Corneal integrity was preserved without hyperplasia in the trial group. A notable reduction in IL-6 expression was observed compared to the positive control.
CONCLUSION: Ghrita Manda demonstrates potential as an effective DE therapy, offering lubrication, corneal protection, and anti-inflammatory benefits, aligning with Ayurvedic principles for managing vata pitta derangements of the ocular surface.
METHODOLOGY: 12 male Swiss albino mice (24 eyes) were divided into: saline-treated controls (3 mice), and dry eye-induced mice treated with either Ghrita Manda (Trial), preservative-free eye drops (Positive control), or left untreated (Negative control). Assessments included Tear Film Break-Up Time (TFBUT), fluorescein scores, corneal Hematoxylin and Eosin (H&E) staining, and IL-6 expression after 14 days.
RESULTS: Ghrita Manda significantly improved TFBUT and reduced fluorescein scores compared to the negative control (p < 0.001). Corneal integrity was preserved without hyperplasia in the trial group. A notable reduction in IL-6 expression was observed compared to the positive control.
CONCLUSION: Ghrita Manda demonstrates potential as an effective DE therapy, offering lubrication, corneal protection, and anti-inflammatory benefits, aligning with Ayurvedic principles for managing vata pitta derangements of the ocular surface.